Superworth

Enovis CORP ENOV

Medical - Instruments & Supplies, Healthcare
$20.62
+3.57%
Market cap
$1.2B
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
0.5×
EV/EBIT
189×
Revenue, 12 months
$2.3B
+5% on a year ago
Net margin
−48.0%
Free cash flow yield
5.4%

Enovis CORP trades at 0.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $2.3B over the last twelve months, up 5% on a year earlier with a −48% net margin.

Charts

Financials

Income statement for ENOV, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$417.5M+9%$455M+11%$516.3M+27%$525.2M+23%$505.2M+21%$561M+23%$558.8M+8%$564.5M+8%$548.9M+9%$575.8M+3%$589.2M+5%$582.8M+3%
Cost of revenue$174.6M+4%$190.6M+8%$218.4M+28%$236.3M+31%$218.8M+25%$253.5M+33%$226.6M+4%$229.8M−3%$220M+1%$226.3M−11%$223.7M−1%$223.5M−3%
Gross profit$243M+13%$264.4M+14%$297.9M+27%$288.9M+16%$286.5M+18%$307.5M+16%$332.2M+12%$334.7M+16%$328.9M+15%$349.4M+14%$365.5M+10%$359.2M+7%
R&D$19.9M+28%$18.3M+24%$23.4M+29%$23.5M+24%$20.5M+3%$24M+31%$28.5M+22%$30.7M+31%$29.7M+45%$31.4M+31%$31.5M+11%$31.7M+3%
SG&A$204.2M+12%$211M+1%$255.7M+23%$264.1M+27%$249.9M+22%$257.7M+22%$269M+5%$267.1M+1%$263.6M+6%$270.4M+5%$282.8M+5%$263.7M−1%
−$20.5M+14%−$5.8M−80%−$35M+40%−$44.2M+205%−$31.7M+55%−$664.7M+11451%−$46.8M+34%−$16.8M−62%−$558.5M+1660%−$502.2M−25%$6.5M$17.4M
Interest expense$5.8M−9%$4.3M−30%$20M+254%$17M+316%$11.1M+92%$9.1M+113%$9.2M−54%$9.3M−45%$8.8M−20%$7.5M−17%$9.2M−0%$8M−14%
Pre-tax income−$25.5M−67%$7.7M−$79.2M+165%−$27.4M+42%−$42.6M+67%−$673.7M−$57.3M−28%−$25.7M−6%−$566.9M+1231%−$509.5M−24%$634K$7.5M
−$6.1M−51%$4.6M−91%−$7.4M+4%−$8.9M+89%−$9.1M+50%$29.9M+552%−$1.8M−76%$10.8M$4M$9.3M−69%$9M$8.5M−21%
Net income−$2.9M−96%$3M−$72M+208%−$18.6M+87%−$31.5M+995%−$703.3M−$56M−22%−$36.7M+97%−$571.1M+1712%−$520.6M−26%−$8.8M−84%−$1.2M−97%
−$0.05−96%$0.05−$1.32+207%−$0.34+89%−$0.58+1060%−$12.59−$0.98−26%−$0.64+88%−$9.99+1622%−$9.10−28%−$0.15−85%−$0.02−97%
54.5M+1%54.6M+1%54.7M+1%54.9M+1%55.7M+2%55.9M+2%56.8M+4%57.1M+4%57.2M+3%57.2M+2%57.3M+1%57.6M+1%

Revenue: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

Cost of revenue: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

Gross profit: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

R&D: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

SG&A: Q1 FY10: 6 months less the 3 months printed beside them.

Operating income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

Interest expense: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

Pre-tax income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

Income tax: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

Net income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

EPS, diluted: 11 periods, Q4 FY12 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY11: share-days: the 6-month average less the second quarter's. 8 periods, Q4 FY12 to Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days. 6 periods, Q4 FY17 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Instruments & Supplies nearest Enovis CORP's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
ENOVEnovis CORP$1.2Bn/m24.0×0.5×+5%−48.0%
STAAStaar Surgical$1.3B356×144×3.7×+51%1.1%
BVSBioventus$1.1B17.1×27.1×1.9×+4%9.4%
IARTIntegra Lifesciences$1.1B80.1×46.3×0.6×+1%0.8%
CDRECadre$1.3B38.9×35.9×2.0×+20%5.3%
EYENational Vision$1.4B28.1×52.7×0.7×+8%2.5%
IRMDIradimed$1B42.5×41.5×11.4×+11%26.8%
LMATLemaitre Vascular$1.9B28.5×42.0×7.1×+12%25.0%
INSPInspire Medical Systems$1.9B14.5×56.6×2.2×−0%15.0%
MOVMovado$710.9M17.7×13.4×1.0×+5%6.0%
UFPTUFP Technologies$2.2B30.6×25.6×3.5×+7%11.4%
Peer median$1.3B29.6×41.7×2.1×+8%7.7%

More on Enovis CORP

Each number over time

Its groups

About

Industry
Medical - Instruments & Supplies
Sector
Healthcare

Valuation data, not investment advice. Prices as of .